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DNA Methylation Changes Following 5-azacitidine Treatment  
in Patients with Myelodysplastic Syndrome
DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic 
syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 
25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, 
and IGSF4 gene was detected in 9/44 patients. In concordance with the clinical response, a 
lack of or decreased methylation in 4 patients with hematologic improvements and 
persistent methylation in 4 others with no response was observed. The mRNA expression of 
CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that 
methylation changes contribute to disease pathogenesis and may serve as marker to 
monitor the efficacy of treatments.
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INTRODUCTION
Myelodysplastic syndrome (MDS) is a clonal stem cell disorder 
characterized by ineffective hematopoiesis in one or more of 
the lineages in the bone marrow and an increased tendency to-
wards acute leukemia transformation (1). MDS patients were 
treated with supportive care measures only; high-dose chemo-
therapy programs modeled after acute myelogenous leukemia 
(AML) therapy or allogenic stem cell transplantation (1, 2). Re-
cently, 5-azacitidine (AC) and 5-aza-2-deoxycitidine (DAC) have 
been used as hypomethylating agents for the treatment of MDS.
  The aberrant methylation of CpG islands or CpG sites, in or 
near the promoter region of many genes was found to be asso-
ciated with the transcriptional inactivation of important tumor 
suppressor genes (TSG) (3-5). These TSG are also often silenced 
in hematopoietic malignancies by DNA hypermethylation (6). 
Many of these genes plays roles in multiple fundamental path-
ways that include cell cycle control (p16INK4a, p15INK4a, Rb1, 
p27Kip1, p14ARF, and p73), DNA repair (BRCA1 and MGMT), 
apoptosis inhibition (DAPK, TMS1, and caspase-8), tumor in-
vasion/metastasis (E-cadherin, APC, TIMP3, and VHL), and 
growth factor responses (ER and EphA3) (7). The DNA methyl-
transferase (DNMT) inhibitors AC and DAC can induce the func-
tional re-expression of genes silenced by cancer that cause growth 
arrest and apoptosis in tumor cells (8). The p15 (CDKN2B) of 
hypermethylation genes may play a causal role in hematologic 
malignancies such as MDS and AML (3). The methylation of p15 
occurs in patients with these disorders and is associated with an 
increased frequency (or density) and advanced disease (9, 10). 
In response to the treatment with AC, one study showed remark-
able differential demethylation in several myeloid leukemia cell 
lines and a significant but transient demethylation in MDS pa-
tients. Genomic DNA methylation patterns have revealed wide-
spread demethylation in array-based analysis (11). 
  Recently, AC and DAC are clinically active in MDS (12-14) and 
other hematologic malignancies. Therapeutic strategies have 
been developed to effectively inhibit methylation in these and 
other malignancies such as CDKN2B (15) that can be reactivat-
ed after treatment with methylation inhibitors. The aberrant 
methylation of CpG islands represents an ideal candidate for 
diagnostic and prognostic cancer markers (16). 
  We analyzed expression and methylation changes of 25 TSG 
identified as potential epigenetic markers after Vidaza
® (azaciti-
dine; AC) treatment in MDS that further the correlation to clinical 
response. Based on a complete cell blood count (CBC) and bone 
marrow findings, our data indicates that methylation changes Tran HTT, et al.  •  Methylation Changes by 5-azacitidine
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after AC treatment were correlated with the clinical responses 
of patients. Our study also confirmed that methylation was as-
sociated with a reduced mRNA expression in patients with MDS. 
Thus, DNA methylation changes can be used as a biomarker in 
predicting the response to a particular chemotherapeutic agent.
 
MATERIALS AND METHODS
Patient samples
A total of 44 MDS patients (30 men and 14 women; age range, 
15-82 yr), including 13 with refractory anemia (RA), one case of 
RA with ringed sideroblasts (RARS), 9 cases of refractory cyto-
penia with multilineage dysplasia (RCMD), one case of refrac-
tory cytopenia with multilineage dysplasia and ringed sidero-
blasts (RCMD-RS), 9 cases of RA with excess blasts-1 (RAEB-1), 
9 cases of RA with excess blasts-2 (RAEB-2) and 2 cases of MDS-
unclassified (MDS-U) (WHO classification), were examined 
before (as part of the initial diagnostic process) and during treat-
ment with AC. The AC dose for all patients was 75 mg/m
2/d for 
7 days and repeated on a 28-day cycle. The response was as-
sessed prior to each cycle of treatment. Therapy was continued 
for three cycles after complete remission (CR) or until progres-
sive disease or toxicity in patients with partial remission (PR) or 
hematologic improvement (HI). Blood was obtained before or 
at the beginning of the first cycle (as before treatment) and at 
the beginning of the 4th, 5th, and 6th cycles (in turn as after 3, 4, 
and 5 cycle’s treatment). The characteristics of the patients are 
summarized in Table 1. Samples were obtained from patients 
who were admitted between 2004 and 2008 at Chonnam Nation-
al University Hwasun Hospital (Jeonnam, Korea). Peripheral 
blood (PB)-MNCs from 3 healthy donors served as non-malig-
nant controls.
DNA methylation and fragment analyses
Genomic DNA was extracted from PB using a QIAamp DNA 
Blood Mini kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s protocol. An ME001 probe mix kit was used for 
methylation-specific multiplex ligation-dependent probe am-
plification (MS-MLPA), according to the manufacturer’s instruc-
tions (MRC-Holland, Amsterdam, Netherlands). The kit contains 
25 sequences corresponding to TSG that are frequently silenced 
by methylation in different tumors but are unmethylated in the 
blood-derived DNA of healthy individuals. MS-MLPA starts with 
sample DNA denaturation and the hybridization of the MLPA 
probes their specific DNA targets. Methylated hybrids of the 
sample DNA are prevented from being digested by HhaI, and 
are then amplified by PCR to generate a signal on an ABI 3100 
sequencer (Applied Biosystems, Foster City, CA, USA). The data 
shown are the mean of triplicate reactions.
  Data normalization and analysis were performed using the 
built-in MLPA application in GeneMarker ver. 1.5 (Soft-Genet-
ics). To determine the methylation status, the normalized height-
ratio data for each ligated sample were compared with the height-
ratio data for the same sample after digestion with HhaI. Aber-
rant methylation was scored when the calculated methylation 
was > 10% (hypermethylation). Percentages below this level 
were regarded as background.
RNA isolation and quantitative real-time RT-PCR
RNA was extracted using the Trizol reagent (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s instructions. 
First-strand cDNA was synthesized from RNA using random 
primers and a Moloney murine leukemia virus (MMLV) reverse 
transcriptase, according to the manufacturer’s protocol. For the 
quantification of CDKN2B, FHIT, IGSF4, and ESR1 transcripts, 
real-time PCR was performed using a 72-well Rotor-Gene RG-
3000 (Corbett Research, Sydney, Australia) with a 10 μL final re-
action mixture containing 250 nM in each primer, 1 × SYBR pre-
mix Ex Taq (Takara, Tokyo, Japan), and 2 μL of cDNA. The prim-
er sequences and annealing temperatures used to amplify each 
of the genes tested are listed in Table 2. The reaction mixture 
was preheated to 95°C for 10 sec, followed by 45 cycles of 95°C 
for 10 sec, 60°C for 20 sec, and 72°C for 20 sec. As a reference 
transcript for each expression level, the housekeeping gene β2-
microglobin was amplified. All reactions included negative con-
trols where the reverse transcriptase was omitted. 
Table 1. Characteristics of the study group (44 patients)
Characteristic    No. (%)
≥ 60 yr old 31 (70.5)
Number of females  14 (31.8)
WHO 
   Low-risk (RA, RARS, RCMD, and unclassified)
   High-risk (RAEB-1 and RAEB-2)
 
26 (59)
18 (41)
IPSS 
   Low 
   Intermediate 1
   Intermediate 2
   High
 
3 (6.8)
27 (61.4)
11 (25)
3 (6.8)
Blast ≤ 5% 26 (59)
Response after three or four cycles 22 (50)
Methylation of at least one gene 9 (20.5)
WHO, World Health Organization; RA, refractory anemia; RARS, RA with ringed sidero
-
blasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, RA with excess 
blasts; IPSS, International Prognostic Scoring System.
Table 2. Primers used for quantitative real-time PCR
Target
Product  
size (bp)
GenBank Primer sequence (5´-3´)
CDKN2B 129 NM_078487.2 F: TGATTAGCACTTGGGTGACG
R: CCTCCTCCACTTTGTCCTCA
FHIT 140 NM_002012.1 F: AAACATTTCCATGGGACCTCTCT
R: GAGCTCCTCATAGATGCTGTCATTC
IGSF4 129 NM_014333 F: CTGGTCCCACCACGTAATCT
R: GTTCCCTTTGAACCACCTGA
ESR1 108 NM_004451.3 F: CCTATCTCAGGGAGGGAAGG
R: TGCTCTCCAAGTCCCACTCTTran HTT, et al.  •  Methylation Changes by 5-azacitidine
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Statistical analysis 
For the mRNA data, 95% confidence intervals (CIs) were calcu-
lated to assess the significance of the 2
-∆∆CT (17). Differences in 
continuous variables were analyzed by the Mann-Whitney U-
test for distributions between two groups. All statistical analyses 
were performed using SPSS software (ver.12.0). For all analyses, 
the P values were two-tailed; a P values < 0.05 was considered 
statistically significant.
Ethics statement
This study was approved by the institutional review board of the 
Chonnam National University Hwasun Hospital in Hwasun, 
Korea (IRB number: CNUHHIRB 2009-22). At the time of PB col-
lection, all case and control subjects provided informed consent 
to participate in this study.
 
RESULTS
Methylation status in MDS patients and methylation 
reversal after 3-5 courses of AC treatment corresponded 
to the clinical response
Alterations in DNA methylation are common in a variety of tu-
mors, as well as during development (18). All MDS patients at 
the time of diagnosis were screened for gene methylation; only 
those samples containing at least one methylated gene, were 
analyzed further by MS-MLPA following 3-5 cycles of AC. The 
PB in this study is similar to that taken previously (10, 11, 20, 24). 
Hypermethylation of at least one gene was detected in 9/44 cases 
(20.5%) that included CDKN2B, FHIT, IGSF4, and ESR1 in MDS 
(Table 3), but not in any of the control samples. Our results in-
dicate increased methylation among high-risk patients (5/18, 
27.8%) compared with low-risk patients (4/26, 15.4%) (P < 0.05). 
Either CDKN2B or ESR1 was methylated in 5 patients (5/44, 
11.4%), whereas FHIT and IGSF4 was methylated in 3 patients 
(3/44, 6.8%) and 2 patients (2/44, 4.5%) respectively. 
  We examined the methylation status of 25 TSG after 3-5 cour-
ses of AC treatment in 9 MDS patients with methylation at the 
time of diagnosis, and assessed the subsequent change in meth-
ylation in association with the correlative clinical response. At 
the time that blood was obtained after treatment, the clinical re-
sponse was evaluated respectively. Increased or reduced meth-
ylation level of at least 10% is considered reinforcement or reduc-
tion respectively. Our data revealed an agreement between de-
methylation and the clinical response in 8 of 9 cases (Table 4). 
Patients (P20, P25, P22, and P24) had the persistent methylation 
that correlated to either no clinical response or tends to leuke-
mia. Specially, P24 (RAEB-2 subtype) progressed to leukemia, 
showed increased methylation level at ESR1 and IGSF4 as well 
as de novo methylation of CDKN2B. The pretreated methylated 
genes were reduced or loss for 3 patients (P16, P34, and P46) who 
exhibited an increase in hematologic improvement (HI). In pa-
tients P34 and P46, no methylation was observed after treatment. 
Patient P16 exhibited ESR1 and FHIT methylation and then re-
mained only ESR1. In the case of patient P7, the results indicat-
Table 3. Methylation frequencies of tumor suppressor genes in 44 AC-treated MDS patients 
Gene  Function Location
Methylated
No. %
TIMP3 Apoptosis regulation, Tyrosine kinase signalling  22q12.3 0 0
APC  Wnt signalling, Cell adhesion 5q21-q22 0 0
CDKN2A/p14-ARF  Cell cycle control, Apoptosis regulation 9p21 0 0
MLH1  Cell cycle control, Mismatch repair 3p22.1 0 0
ATM  DNA repair, Apoptosis regulation, Cell cycle control, TLR signalling  11q23 0 0
RARβ Transcription regulation, Signal transduction 3p24 0 0
CDKN2B/p15  Cell cycle control 9p21 5 11
HIC1  Cell cycle control, Transcription regulation 17p13.3 0 0
CHFR  Cell cycle control, Ubiquitination  12q24.33 0 0
PAH  L-phenylalanine catabolism, Amino acid biosynthesis 12q23 0 0
CASP8  Apoptosis regulation 2q33.2 0 0
CDKN1B/p27  Cell cycle control 12p13.2 0 0
PTEN  Cell adhesion, Apoptosis regulation, Cell cycle control 10q23.3 0 0
BRCA2  DNA repair, Cell cycle control 13q12.3 0 0
CD44  Cell adhesion 11p212 0 0
DAPK1  Apoptosis regulation 9q34.1 0 0
TP73  Cell cycle control 1p36 0 0
VHL  Transcription factor binding Apoptosis regulation, Cell cycle control 3p25.3 0 0
ESR1  Transcription regulation, Signal transduction, Cell growth regulation 6q25.1 5 11
RASSF1  Cell cycle control, Ras signalling 3p21.3 0 0
FHIT  Cell cycle control, Nucleotide metabolism 3p14.2 3 7
IGSF4  Cell adhesion 11q23 2 4.5
CDH13  Cell adhesion 16q24.2 0 0Tran HTT, et al.  •  Methylation Changes by 5-azacitidine
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ed a loss of ESR1 and remained FHIT methylation with no ac-
companying clinical response after 3 courses (the patient re-
fused the fourth course of AC); however, hematologic improve-
ment was observed in this patient after follow-up. It is possible 
that the therapeutic effect may be delayed with a response oc-
curring several weeks after treatment (19). Although patient P29 
(RCMD subtype) had no clinical response, the methylation at 
CDKN2B disappeared after 5 courses of AC. 
  Methylation status of CDKN2B and FHIT using pyrosequenc-
ing in MDS patients with methylation at the time of diagnosis 
was confirmed in the association shown between DNA methyla-
tion reversal and a clinical response (data not shown). The meth-
ylation status changed following 3-5 courses of AC, a demethyl-
ation agent, (correlated with the clinical response observed), 
based on recommended criteria.
Reduced gene expression in the MDS patients versus 
controls 
The transcriptional silencing of TSG associated with DNA meth-
ylation is a common epigenetic event in hematologic malignan-
cies. To verify the contribution of DNA methylation to the inac-
tivation of transcription, we compared mRNA expression levels 
in the MDS and control group. The mean level of mRNA expres-
sion for CDKN2B, FHIT, IGSF4, and ESR1 was higher in the con-
trol group (16 PB samples) than in the MDS group (30 PB samples) 
(Fig. 1). The difference for CDKN2B, IGSF4, and ESR1 mRNA 
Table 4. Methylation reversal in AC-treated MDS patients and their clinical responses
ID Age/Sex  WHO  IPSS Genes
Methylated genes
Clinical response
at diagnosis after AC
P7 (V3) 72/M RAEB-1 1.5 FHIT
ESR1
0.176
0.143
0.197
U
HI
P16 (V3) 52/M RA 1 FHIT
ESR1
0.106
0.173
U
0.155
HI
P20 (V3) 71/F RA 0.5 CDKN2B
ESR1
0.954
0.335
1.162
0.493
NR
P22 (V3) 53/M RAEB-2 2 CDKN2B 0.153 0.1 P
P24 (V3) 62/F RAEB-2 2 CDKN2B
IGSF4
ESR1
U
0.139
0.274
0.111
0.3
0.554
P
P25 (V5) 15/F RAEB-1 1 ESR1 0.43 0.417 NR
P29 (V5) 43/F RCMD 0.5 CDKN2B 0.169 U NR
P34 (V4) 64/M RA 1 CDKN2B
FHIT
0.113
0.113
U
U
HI
P46 (V4) 68/F RAEB-2  2.5 CDKN2B
IGSF4
0.169
0.255
U
U
HI
V (No.), number of cycles of AC treatment; U, Unmethylated; HI, Hematologic improvement; NR, no response; P, progression to AML.
Fig. 1. Quantitative analysis of mRNA expression of CDKN2B, FHIT, IGSF4, and ESR1 in 30 MDS patients and 16 normal controls were analyzed at diagnosis. MDS group was 
significantly lower level in CDKN2B, IGSF4, and ESR1 (P < 0.05). The horizontal bars indicate the median value for each sample group.
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expression was statistically significant (P < 0.05) whereas the 
difference for FHIT was not (P = 0.343). Additionally, most of 
the individuals for whom CDKN2B, FHIT, IGSF4, and ESR1 were 
initial methylated showed reduced mRNA compared with the 
median value. Despite the lack of a clinical response in the 9 sam-
ples (in terms of their mRNA levels after 3 5 courses of AC), we 
also found evidence for the reactivation of gene expression in 
response to the demethylation agent (Fig. 2).
DISCUSSION
Many genes important for most of the carcinogenic pathways 
are hypermethylated in MDS (7). DNMT inhibitors, that inhibit 
DNA methylation in various studies (15, 20, 21), represent a ma-
jor advance in treatment (13, 14); however, it is still unclear wheth-
er methylation reversal corresponds to a clinical response. The 
present study examined genome-specific methylation changes 
in MDS patients who received conventional AC treatment using 
MS-MLPA. Our results indicate a higher degree of methylation 
among high-risk patients (5/18, 27.8%) versus low-risk patients 
(4/26, 15.4%; P < 0.05), similar to previous reports (9, 22). Inter-
estingly, a correlation was detected between clinical responses 
based on conventional hematologic improvement and quanti-
tative gene methylation dynamics that followed 3-5 courses of 
AC treatment. 
  Many studies have shown that the demethylation and reacti-
vation of some genes correlate with drug responses to DAC and 
AC in primary cells such as MDS patients (15, 21), and AML (20). 
In addition, the large-scale demethylating activity of AC was 
shown in a subset of MDS patients (11). These results are simi-
lar to the result that responding patients with a partial recovery 
(or complete recovery) showed a reduction in or the absence of 
methylated genes and that patients with an AML transformation 
(or no response) showed the maintenance to reinforcement of 
methylation status after treatment. However, Raj et al. (23) showed 
an AC reduced CDKN2B methylation uncorrelated with the re-
sponse. Currently, no association between the clinical response 
and baseline methylation or methylation reversal in the bone 
marrow or purified CD34
+ cells was reported (24). 
  The authors focused on molecular changes during cycle 1 to 
ensure the study of proximal changes in the diseased cells. How-
ever, our present findings indicate that important epigenetic al-
terations may occur in later cycles. The poor responses of the 
patients with strong methylation (such as P20, P24, and P25) sug-
gest the need for tailored therapy (alternative doses and combi-
nation strategies) to optimize their responses. It was previously 
shown that methylation reversal during cycle 1 predicted the 
clinical response in MDS/AML patients treated with AC and 
phenylbutyrate (25). A limited response in cytopenia was de-
tected in patient P29; however, a lack of CDKN2B hypermethyl-
ation and reactivation of mRNA expression was detected earlier 
during AC treatment. This indicated that the demethylating agent 
became activated and that other unknown mechanisms may 
have prevented hematologic improvements (i.e., a demethyl-
ation-independent response). In their review, Silverman et al. 
(26) presented a mechanism for a hematologic response, with 
an AC blocking leukemia inhibitory factor, oncostatin M, inter-
leukin (IL)-6, and IL-11; alternatively; AC may act as a biologi-
cal response modifier to restore normal hematopoiesis. It is pos-
sible that the methylation/demethylation of genes other than 
Fig. 2. Demethylation due to AC treatment in the methylated samples was associated with mRNA re-expression in the MDS group after 3-5 treatment cycles. Data shown are 
representative of three independent experiments. P means patient number.
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CDKN2B is critical to this response (7). Taken together, these 
data indicate that methylation reversal can be used as a molec-
ular marker following AC treatment. Consistent with this, gene 
methylation increased during disease progression with little to 
no reversal occurring after AC treatments in conjunction with 
the lack of a clinical response or leukemic transformation may 
be indicative of a poor prognosis.
  The most widespread epigenetic abnormality in tumorigen-
esis is the silencing of a gene transcription associated with a rise 
in DNA methylation in normally unmethylated gene promoter 
regions. In this study, we found that the mRNA expression of 
several methylated genes, including CDKN2B, IGSF4, and ESR1, 
in the MDS group was reduced at the time of the initial diagno-
sis of the patient. In contrast, the mRNA expression of FHIT in 
MDS was not significantly altered when compared with the con-
trols. The results indicate that CDKN2B, IGSF4, and ESR1 expres-
sion is involved in the pathogenesis of MDS at an early stage 
while FHIT expression appears to be important at a later phase 
in the development of MDS (27). Additionally, because the ex-
pression level decreased in association with methylation at the 
time of diagnosis (while the expression level increased in response 
to treatment with AC) the reduction in transcription caused by 
methylation might be involved in the pathogenesis and disease 
progression of MDS. 
  When compared with the incidences reported by others (29), 
e.g. for p15 (15), and for FHIT (27), low methylation incidences 
in this study were observed. This may be due to the underesti-
mation for the methylation of TSG such as a limited number of 
CpGs in MS-MLPA (28), detection in non-purification of malig-
nant cells and low frequency (41%) patients with a blast more 
than 5%. We also omitted clinical responders without baseline 
methylation that seemed to mask potential associations between 
the reversal of methylation and a clinical response. Thus, other 
means of controlling the response of patients (such as histone 
code or apoptosis) should be considered.
  In conclusion, changes in methylation caused by AC treatment 
may contribute to the clinical response of patients, as shown by 
the improvement of specific hematologic factors in our study. 
Demethylation agent-induced treatment is associated with hy-
pomethylation and the reestablishment of a gene-specific ex-
pression. The sustained response observed in patients with AC 
requires validation in a larger cohort. Additional studies that in-
clude the identification of relevant TSG for drug-induced de-
methylation are needed to confirm the results.
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DNA methyltransferase inhibitor, 5-azacitidine (AC), which is effective in myelodysplastic syndromes (MDS), can induce re-
expression in cancer. We analyzed methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, 
FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients. In concordance with clinical response, a lack or decreased methylation 
in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed. mRNA 
expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that methylation changes 
contribute to disease pathogenesis and may serve as a marker to monitor efficacy of AC treatment.